XTX501 — IND submission
2026
Xilio is currently advancing XTX501 through investigational new drug (IND)-enabling studies and plans to submit an IND application in the middle of 2026.Source filing
XLO biotech catalysts & pipeline
XILIO THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
CLDN18.2 and PSMA+STEAP1 programs — IND submission
in 2027
Xilio plans to submit IND applications for its CLDN18.2 and PSMA+STEAP1 programs in 2027.Source filing
efarindodekin alfa — Full data
H1 2027
Xilio is evaluating efarindodekin alfa as a monotherapy in an ongoing Phase 2 clinical trial in patients with advanced solid tumors and expects to deliver an option data package to Gilead Sciences, Inc. (Gilead) in the first half of 2027.Source filing
masked T cell engagers — IND submission
in 2027
Xilio plans to advance these masked T cell engager programs into IND-enabling studies and submit IND applications for each of these programs in 2027.Source filing
PSMA+STEAP1 SEECR — IND submission
2027
PSMA+STEAP1 SEECR: IND submission (2027)Source filing
CLDN18.2 — IND submission
H2 2027
Xilio plans to submit INDs for its CLDN18.2 and PSMA+STEAP1 programs in the second half of 2027.Source filing
PSMA and STEAP1 — IND submission
H2 2027
Xilio plans to submit INDs for its CLDN18.2 and PSMA+STEAP1 programs in the second half of 2027.Source filing
XTX501 — Initial data
H2 2027
We expect to initiate dosing in the Phase 1 portion of the trial in patients with metastatic non-small cell lung cancer, or NSCLC, and select advanced solid tumors in the second half of 2026, and we plan to report initial Phase 1 data in patients with metastatic NSCLC in the second half of 2027.Source filing